U.S. markets closed

Silverback Therapeutics, Inc. (SBTX)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
5.08-0.10 (-1.93%)
At close: 04:00PM EDT
5.00 -0.08 (-1.57%)
After hours: 06:57PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Slow Stochastic

Slow Stochastic

Previous Close5.18
Bid5.04 x 800
Ask5.07 x 800
Day's Range5.00 - 5.32
52 Week Range2.80 - 31.72
Avg. Volume440,256
Market Cap178.751M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-2.73
Earnings DateNov 08, 2022 - Nov 14, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est5.00
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value

Subscribe to Yahoo Finance Plus to view Fair Value for SBTX

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Silverback Therapeutics, Inc.
    Daily – Vickers Top Buyers & Sellers for 06/15/2022The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
    Fair Value
    Economic Moat
    2 months agoArgus Research
View more
  • American City Business Journals

    Silverback Therapeutics plans merger with San Diego biotech

    The move comes months after Seattle-based Silverback shuttered its oncology program. The combined company will focus on an epinephrine nasal spray called Neffy.

  • Benzinga

    Once A Cancer Company, Silverback Merges With Small Biotech Working On Allergy Treatment

    ARS Pharmaceuticals Inc will merge with Silverback Therapeutics Inc (NASDAQ: SBTX) in an all-stock transaction, with a new entity operating under the ARS Pharmaceuticals name and trade on NASDAQ under the SPRY symbol. The combined company will focus on neffy, ARS's investigational epinephrine nasal spray for Type I allergic reactions, including anaphylaxis. The combined entity is expected to have approximately $265 million in cash and equivalents at closing. Also Read: Silverback Therapeutics Ax

  • Business Wire

    Silverback Therapeutics and ARS Pharmaceuticals Announce Merger

    SEATTLE & SAN DIEGO, July 21, 2022--Silverback Therapeutics, Inc. (Nasdaq: SBTX) ("Silverback") and ARS Pharmaceuticals, Inc. ("ARS") today announced that the companies have entered into a definitive agreement under which ARS will merge with Silverback in an all-stock transaction. The combined company will focus on the potential regulatory approval and commercialization of neffy, ARS’s investigational epinephrine nasal spray for the treatment of Type I allergic reactions including anaphylaxis. T